Suggested Topics within your search.
Showing 361 - 400 results of 25,514 for search '"review"', query time: 0.20s Refine Results
  1. 361
    Pharmacoeconomic review report. Ozenoxacin 1% cream (Ozanex), (Ferrer internacional, S.A.) : indication : the topical treatment of impetigo in patients aged two months and older.

    Pharmacoeconomic review report. indication : the topical treatment of impetigo in patients aged two months and older.

    Published 2018
    Full text
    Electronic eBook
    Save to List
    Saved in:
  2. 362
    Clinical review report. Letermovir (Prevymis) (Merck Canada Inc.).

    Clinical review report. Letermovir (Prevymis) (Merck Canada Inc.).

    Published 2018
    Full text
    Electronic eBook
    Save to List
    Saved in:
  3. 363
    Clinical review report. Dexamethasone (Ozurdex) (Allergan, Inc.) : indication for the treatment of adult patients with diabetic macular edema who are pseudophakic.

    Clinical review report. indication for the treatment of adult patients with diabetic macular edema who are pseudophakic.

    Published 2018
    “…Common drug review clinical review report.…”
    Full text
    Electronic eBook
    Save to List
    Saved in:
  4. 364
    Clinical review report. Dupilumab (Dupixent) (Sanofi-Aventis Canada Inc.) : indication: moderate-to-severe atopic dermatitis (AD).

    Clinical review report. indication: moderate-to-severe atopic dermatitis (AD).

    Published 2018
    Full text
    Electronic eBook
    Save to List
    Saved in:
  5. 365
    Pharmacoeconomic review report. Emtricitabine/tenofovir alafenamide (Descovy).

    Pharmacoeconomic review report. Emtricitabine/tenofovir alafenamide (Descovy).

    Published 2016
    Full text
    Electronic eBook
    Save to List
    Saved in:
  6. 366
    Pharmacoeconomic review report. Letermovir (Prevymis) (Merck Canada Inc.).

    Pharmacoeconomic review report. Letermovir (Prevymis) (Merck Canada Inc.).

    Final pharmacoeconomic review report (with redactions).
    Published 2018
    Full text
    Electronic eBook
    Save to List
    Saved in:
  7. 367
    Pharmacoeconomic review report. Dexamethasone (Ozurdex) (Allergan Inc.).

    Pharmacoeconomic review report. Dexamethasone (Ozurdex) (Allergan Inc.).

    Final with redactions.
    Published 2018
    Full text
    Electronic eBook
    Save to List
    Saved in:
  8. 368
    Pharmacoeconomic review report. Dupilumab (Dupixent) (Sanofi-Aventis Canada Inc.).

    Pharmacoeconomic review report. Dupilumab (Dupixent) (Sanofi-Aventis Canada Inc.).

    Final Pharmacoeconomic Review Report (with redactions).
    Published 2018
    Full text
    Electronic eBook
    Save to List
    Saved in:
  9. 369
    Pharmacoeconomic review report. Sebelipase Alfa (Kanuma) (Alexion pharmaceuticals, Inc.).

    Pharmacoeconomic review report. Sebelipase Alfa (Kanuma) (Alexion pharmaceuticals, Inc.).

    Published 2018
    Full text
    Electronic eBook
    Save to List
    Saved in:
  10. 370
    Clinical review report. Ticagrelor (Brilinta) : indication : co-administered with low-dose acetylsalicylic acid (ASA: 75-150 mg), is indicated for the secondary prevention of atherothrombotic events in patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing an atherothrombotic event.

    Clinical review report. indication : co-administered with low-dose acetylsalicylic acid (ASA: 75-150 mg), is indicated for the secondary prevention of atherothrombotic events in patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing an atherothrombotic event.

    Published 2016
    Full text
    Electronic eBook
    Save to List
    Saved in:
  11. 371
    Clinical review report. Tesamorelin (Egrifta) : indication : treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference [greater than or equal to] 95 cm for males and [greater than or equal to] 94 cm for females, and confirmed by a VAT level > 130 cm² by computerized tomography scan, in treatment-experienced adult human immunodeficiency virus-infected patients with lipodystrophy.

    Clinical review report. indication : treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference [greater than or equal to] 95 cm for males and [greater than or equal to] 94 cm for females, and confirmed by a VAT level > 130 cm² by computerized tomography scan, in treatment-experienced adult human immunodeficiency virus-infected patients with lipodystrophy.

    Published 2016
    Full text
    Electronic eBook
    Save to List
    Saved in:
  12. 372
    Clinical review report. Adalimumab (Humira) : indication : for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy including corticosteroids, azathioprine and/or 6-mercaptopurine (6-MP) or who are intolerant to such therapies.

    Clinical review report. indication : for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy including corticosteroids, azathioprine and/or 6-mercaptopurine (6-MP) or who are intolerant to such therapies.

    Published 2016
    Full text
    Electronic eBook
    Save to List
    Saved in:
  13. 373
    Clinical review report. Sebelipase alfa (Kanuma) (Alexion pharmaceuticals, inc.) : indication: indicated for the treatment of infants, children, and adults diagnosed with lysosomal acid lipase (LAL) deficiency.

    Clinical review report. indication: indicated for the treatment of infants, children, and adults diagnosed with lysosomal acid lipase (LAL) deficiency.

    Final.
    Published 2018
    Full text
    Electronic eBook
    Save to List
    Saved in:
  14. 374
    Pharmacoeconomic review report. Ticagrelor (Brilinta).

    Pharmacoeconomic review report. Ticagrelor (Brilinta).

    Published 2016
    Full text
    Electronic eBook
    Save to List
    Saved in:
  15. 375
    Pharmacoeconomic review report. Obeticholic acid (Ocaliva) : (Intercept Pharma Canada, Inc.) : indication : for the treatment of primary biliary cholangitis.

    Pharmacoeconomic review report. (Intercept Pharma Canada, Inc.) : indication : for the treatment of primary biliary cholangitis.

    Version: final.
    Published 2017
    Full text
    Electronic eBook
    Save to List
    Saved in:
  16. 376
    Clinical review report. Burosumab (Crysvita) (Kyowa Kirin limited) : indication: for the treatment of x-linked hypophosphatemia in adult and pediatric patients one year of age and older.

    Clinical review report. indication: for the treatment of x-linked hypophosphatemia in adult and pediatric patients one year of age and older.

    Final.
    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:
  17. 377
    Clinical review report. Naltrexone hydrochloride and bupropion hydrochloride (Contrave) : (Bausch Health, Canada Inc.) : indication: an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., controlled hypertension, type 2 diabetes mellitus, or dyslipidemia).

    Clinical review report. (Bausch Health, Canada Inc.) : indication: an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., controlled hypertension, type 2 diabetes mellitus, or dyslipidemia).

    Version: Final.
    Published 2020
    “…Clinical review report for Naltrexone hydrochloride and Bupropion Hydrochloride (Contrave)…”
    Full text
    Electronic eBook
    Save to List
    Saved in:
  18. 378
    Clinical review report. Brolucizumab (Beovu) (Novartis Pharmaceuticals Canada Inc.) : indication : treatment of neovascular (wet) age-related macular degeneration (AMD).

    Clinical review report. indication : treatment of neovascular (wet) age-related macular degeneration (AMD).

    Version: Final.
    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:
  19. 379
    Pharmacoeconomic review report. Burosumab (Crysvita), Kyowa Kirin Limited : indication : for the treatment of x-linked hypophosphatemia in adult and pediatric patients one year of age and older.

    Pharmacoeconomic review report. indication : for the treatment of x-linked hypophosphatemia in adult and pediatric patients one year of age and older.

    Version: Final.
    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:
  20. 380
    Clinical review report. Dupilumab (Dupixent) (Sanofi genzyme, a division of Sanofi-Aventis Canada Inc.) : indication : indicated for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

    Clinical review report. indication : indicated for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

    Version: Final.
    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:
  21. 381
    Clinical review report. Belimumab (Benlysta) (GlaxoSmithKline Inc.) : indication : indicated in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus.

    Clinical review report. indication : indicated in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus.

    Version: Final.
    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:
  22. 382
    Clinical review report. Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication : for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to, or are intolerant to conventional therapy.

    Clinical review report. indication : for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to, or are intolerant to conventional therapy.

    Version: Final (with redactions).
    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:
  23. 383
    Pharmacoeconomic review report. Certolizumab pegol (Cimzia) : (UCB Canada Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

    Pharmacoeconomic review report. (UCB Canada Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

    Version: Final.
    Published 2020
    “…Pharmacoeconomic review report for Certolizumab pegol (Cimzia)…”
    Full text
    Electronic eBook
    Save to List
    Saved in:
  24. 384
    Pharmacoeconomic review report. Belimumab (Benlysta) (GlaxoSmithKline Inc.) : indication: indicated in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus.

    Pharmacoeconomic review report. indication: indicated in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus.

    Final (with redactions).
    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:
  25. 385
    Pharmacoeconomic review report. Onabotulinumtoxin A (Botox) (Allergan inc.) : indication: for the prophylaxis of headaches in adults with chronic migraine (plus/minus 15 days per month with headache lasting four hours a day or longer).

    Pharmacoeconomic review report. indication: for the prophylaxis of headaches in adults with chronic migraine (plus/minus 15 days per month with headache lasting four hours a day or longer).

    Final (with redactions).
    Published 2019
    “…Common drug review clinical review report.…”
    Full text
    Electronic eBook
    Save to List
    Saved in:
  26. 386
    Pharmacoeconomic review report. Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication: for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to, or are intolerant to conventional therapy.

    Pharmacoeconomic review report. indication: for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to, or are intolerant to conventional therapy.

    Final.
    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:
  27. 387
    Clinical review report. Certolizumab pegol (Cimzia) (UCB Canada Inc.) : indication: treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

    Clinical review report. indication: treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

    Final (with redactions).
    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:
  28. 388
    Pharmacoeconomic review report. Teduglutide (Revestive) (Shire Pharmaceuticals Ireland Limited) : indication: treatment of adults and pediatric patients one year of age and above with short bowel syndrome who are dependent on parenteral support.

    Pharmacoeconomic review report. indication: treatment of adults and pediatric patients one year of age and above with short bowel syndrome who are dependent on parenteral support.

    Final.
    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:
  29. 389
    Clinical review report. Vortioxetine hydrobromide (Trintellix) (Lundbeck Canada Inc.) : indication: the treatment of major depressive disorder in adults.

    Clinical review report. indication: the treatment of major depressive disorder in adults.

    Corrected version with redactions.
    Published 2020
    “…Common drug review clinical review report.…”
    Full text
    Electronic eBook
    Save to List
    Saved in:
  30. 390
    Clinical review report. Iron isomaltoside 1000 (Monoferric) (Pharmacosmos A/S) : indication: for the treatment of iron deficiency anemia in adult patients who have intolerance or unresponsiveness to oral iron therapy.

    Clinical review report. indication: for the treatment of iron deficiency anemia in adult patients who have intolerance or unresponsiveness to oral iron therapy.

    Final.
    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:
  31. 391
    Clinical review report. Safinamide (Onstryv) (Valeo Pharma Inc.) : indication: for add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson disease (PD) in patients experiencing "off" episodes while on a stable dose of levodopa. Safinamide has not been shown to be effective as monotherapy for the treatment of PD.

    Clinical review report. indication: for add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson disease (PD) in patients experiencing "off" episodes while on a stable dose of levodopa. ...

    Version: final (with redactions).
    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:
  32. 392
    Pharmacoeconomic review report. Safinamide (Onstryv) (Valeo Pharma Inc.) : indication: for add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson disease (PD) in patients experiencing "OFF" episodes while on a stable dose of levodopa. Safinamide has not been shown to be effective as monotherapy for the treatment of PD.

    Pharmacoeconomic review report. indication: for add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson disease (PD) in patients experiencing "OFF" episodes while on a stable dose of levodopa. ...

    Final (with redactions).
    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:
  33. 393
    Pharmacoeconomic review report. Iron isomaltoside 1000 (Monoferric) (Pharmacosmos A/S) : indication: for the treatment of iron deficiency anemia in adult patients who have intolerance or unresponsiveness to oral iron therapy.

    Pharmacoeconomic review report. indication: for the treatment of iron deficiency anemia in adult patients who have intolerance or unresponsiveness to oral iron therapy.

    Final.
    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:
  34. 394
    Pharmacoeconomic review report. Sodium zirconium cyclosilicate (Lokelma) (AstraZeneca Canada Inc.) : indication : for the treatment of hyperkalemia in adult patients..

    Pharmacoeconomic review report. indication : for the treatment of hyperkalemia in adult patients..

    Version: final.
    Published 2020
    “…Common drug review clinical review report.…”
    Full text
    Electronic eBook
    Save to List
    Saved in:
  35. 395
    Clinical review report. Sodium zirconium cyclosilicate (Lokelma) : (AstraZeneca Canada Inc.) : indication: for the treatment of hyperkalemia in adults.

    Clinical review report. (AstraZeneca Canada Inc.) : indication: for the treatment of hyperkalemia in adults.

    Final.
    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:
  36. 396
    Pharmacoeconomic review report. Tafamidis (Vyndaqel) (Pfizer Canada ULC) : indication: for the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis, wild-type or hereditary, to reduce cardiovascular mortality and cardiovascular-related hospitalization.

    Pharmacoeconomic review report. indication: for the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis, wild-type or hereditary, to reduce cardiovascular mortality and cardiovascular-related hospitalization.

    Final.
    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:
  37. 397
    Pharmacoeconomic review report. Vortioxetine hydrobromide (Trintellix) (Lundbeck Canada Inc.) : indication : the treatment of major depressive disorder in adults.

    Pharmacoeconomic review report. indication : the treatment of major depressive disorder in adults.

    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:
  38. 398
    Clinical review report. Tafamidis (Vyndaqel) (Pfizer Canada ULC) : indication: for the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis, wild-type or hereditary, to reduce cardiovascular mortality and cardiovascular-related hospitalization.

    Clinical review report. indication: for the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis, wild-type or hereditary, to reduce cardiovascular mortality and cardiovascular-related hospitalization.

    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:
  39. 399
    Pharmacoeconomic review report. Glucagon nasal powder (Baqsimi) (Eli Lilly Canada Inc.) : indication: for the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates.

    Pharmacoeconomic review report. indication: for the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates.

    Final (with redactions).
    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:
  40. 400
    Clinical review report. Glucagon nasal powder (Baqsimi) (Eli Lilly Canada Inc) : indication: for the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates.

    Clinical review report. indication: for the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates.

    Final (with redactions).
    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:

Search Tools: